BioCentury | Aug 8, 2013
Distillery Therapeutics

Indication: Infectious disease

...targeting angiopoietins, in Phase III or earlier testing for various cancers. Silence Therapeutics plc has Atu111...
BioCentury | Dec 13, 2012
Tools & Techniques

Pulmonary edema on a chip

...of the edema-inducing ANG2 ( ANGPT2 ), inhibited IL-2-induced pulmonary edema. Silence Therapeutics plc has Atu111...
BioCentury | Sep 17, 2012
Clinical News

Silence Therapeutics preclinical data

...In a preclinical model of Streptococcus pneumonia acute lung injury, Atu111 plus antibiotic therapy led to...
...preclinical testing for acute lung injury and sepsis. Silence Therapeutics plc (LSE:SLN), London, U.K. Product: Atu111...
Items per page:
1 - 3 of 3